Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism:: A randomized, placebo-controlled trial.
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- November 16, 2002
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1114 Paediatrics and Reproductive Medicine (FoR)
- Immunology (Science Metrix)
published in
- Blood Journal